SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- LPL Financial Holdings Inc. (Nasdaq: LPLA) (the “Company”) will host an Investor and Analyst Day from 9:00 a.m. to 12:30 p.m. ET on Wednesday, November 16 at Convene 5th Avenue in New York City. A copy of the …
LEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity …
- Acquired Intelligent Fingerprinting Limited and its proprietary drugs of abuse screening technology - - Announced new additions to Board of Directors and name change to Intelligent Bio Solutions Inc. - - Company to host conference call & webcast …
PENNSAUKEN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and …
MONACO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the “Company”) (NYSE: SB), an international provider of marine drybulk transportation services, announced today its unaudited financial results for the three and nine month periods ended …
Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Entered into a secured debt financing agreement for up …
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously Gross Profit Growth and Narrowing Net …
80% increase in GIMOTI® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compared to Q2 13% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a …
Reported positive Phase 1 proof-of-concept data supporting the further development of lead oral IL-17 antagonist, DC-806, as potential best-in-class oral agent for psoriasis Demonstrated direct inhibition of a cytokine with a small molecule in psoriasis …
SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the …
REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and …
- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and 11 Stable Diseases in Advanced Solid Tumors - - Expect to …
DANBURY, CT, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.32 per share, payable on January 4, 2023, to …
COLUMBIA, Md., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tenable®, the Exposure Management company, today announced its Chief Financial Officer, Steve Vintz, is scheduled to attend two upcoming investor conferences, including the Barclays Global Technology, Media …
First Quarter Net Revenue of $31.8 Million, up 15 Percent Year-Over-Year First Quarter GAAP EPS of ($0.05) vs. ($0.08) in the Prior Year First Quarter Non-GAAP EPS of $0.07 vs. $0.08 in the Prior Year Raises Full Year Fiscal 2023 Revenue Guidance to a …
SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of …
Q3 Cannabinoid Revenue Increases 12% Year-Over-Year, with 100% Growth in the Segment Year-to-Date Significant Continued Progress on Cost Reduction Initiatives Driving Sequential Improvements in Adjusted EBITDA Continued Financial Discipline, Operational …
Third Quarter 2022 Net Sales of Approximately $210 Million at the High-End of Guidance Adjusted EBITDA Exceeds Company's Third Quarter Guidance Reports Record Quarterly Cash from Operations of $64.5 Million Raises 2022 Annual Adjusted EBITDA Outlook …
- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - - Start-up activities for Bomedemstat pivotal Phase 3 ET …
Third quarter 2022 net sales were $47.8 million, a decrease of 2.9% (or an increase of 3.1% on a constant currency basis) versus the prior year period; net sales increased 3.0% (or 8.1% on a constant currency basis) for the nine months ended September 30, …
